China Tongbo (01763) fell by more than 6%, down 6.43% at press time to HK$10.48, with a turnover of HK$4.53 million.
The Zhitong Finance App learned that China's Tongbo (01763) fell by more than 6%, down 6.43% at press time, to HK$10.48, with a turnover of HK$4.53 million.
According to the news, the company announced its 2023 results, with revenue of about 6.635 billion yuan, up 7.82% year on year; gross profit fell 1% year on year to 3.482 billion yuan, profit attributable to the company's equity shareholders was about 371 million yuan, a decrease of 5.43% year on year; profit per share was 1.16 yuan, with a recommended final dividend of 31.31 points per share. Among them, pharmaceuticals achieved operating revenue of 4.129 billion yuan, an increase of 5.2% over the previous year. Among them, revenue from radiopharmaceuticals for imaging diagnosis and treatment was 1,683 billion yuan, up 15.3% year on year; revenue from breath testing was 2,324 billion yuan, down 1.0% year on year. The decrease in gross profit was mainly due to lower gross margin of radiation therapy equipment and related services and other business segments, which had a large increase in revenue, which reduced the overall gross profit increase.
In addition, the company released the 2023 annual results report of the subsidiary Atomic Hi-Tech. Atomic Hi-Tech received total operating revenue of 1,578 billion yuan, an increase of 19.32% over the previous year; net profit attributable to shareholders of listed companies was 256 million yuan, an increase of 2.77% over the previous year; and basic earnings per share were 1.585 yuan.